Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam
is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for is urgent. We demonstrate the efficacy of aztreonam-avibactam (ATM-AVI) a...
Gespeichert in:
| Veröffentlicht in: | Antimicrobial agents and chemotherapy 2017-10, Vol.61 (10) |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 61 |
| creator | Mojica, Maria F Papp-Wallace, Krisztina M Taracila, Magdalena A Barnes, Melissa D Rutter, Joseph D Jacobs, Michael R LiPuma, John J Walsh, Thomas J Vila, Alejandro J Bonomo, Robert A |
| description | is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for
is urgent. We demonstrate the
efficacy of aztreonam-avibactam (ATM-AVI) against
and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of
, addressing an unmet medical need. |
| doi_str_mv | 10.1128/AAC.00777-17 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5610502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1927305474</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-9b12b488142c620cfc590d9845616132d656d0eaf569eb57857be4bc8f710af53</originalsourceid><addsrcrecordid>eNp1kUtrGzEUhUVJaVy3u6yDlgl0HEnWazaBwfQRCATidi00siZW0IwcSWNwf33U2DXJIitx7_10rnQOAGcYzTAm8qppFjOEhBAVFh_ABKNaVpzV_ARMEOK8ohLRU_A5pUdUalajT-CUSCEp5_UEPDRb12qTdQ_vbcoh2gTz2sLlmIzdZNc67_IOhg4uvBuc0R7epOB1LlxpLrMdQo5hsw59GHSCvfa5VOWWhjnA5m-Otgz6L-Bjp32yXw_nFPz58f334ld1e_fzZtHcVppimau6xaSlUmJKDCfIdKY8eFVLyjjmeE5WnPEVsrpjvLYtE5KJ1tLWyE5gVLrzKbje627GtrcrY4cctVeb6Hoddypop95OBrdWD2GrygLEECkCFweBGJ7GYonqXbHCez3YMCaFayLmiFFBC_ptj5oYUoq2O67BSP3LRpVs1Es2CouCX-5xnXqiHsMYh-LEe-z5628chf8HN38GfyeYwA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1927305474</pqid></control><display><type>article</type><title>Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Mojica, Maria F ; Papp-Wallace, Krisztina M ; Taracila, Magdalena A ; Barnes, Melissa D ; Rutter, Joseph D ; Jacobs, Michael R ; LiPuma, John J ; Walsh, Thomas J ; Vila, Alejandro J ; Bonomo, Robert A</creator><creatorcontrib>Mojica, Maria F ; Papp-Wallace, Krisztina M ; Taracila, Magdalena A ; Barnes, Melissa D ; Rutter, Joseph D ; Jacobs, Michael R ; LiPuma, John J ; Walsh, Thomas J ; Vila, Alejandro J ; Bonomo, Robert A</creatorcontrib><description>is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for
is urgent. We demonstrate the
efficacy of aztreonam-avibactam (ATM-AVI) against
and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of
, addressing an unmet medical need.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.00777-17</identifier><identifier>PMID: 28784669</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Anti-Bacterial Agents ; Anti-Bacterial Agents - pharmacology ; Azabicyclo Compounds ; Azabicyclo Compounds - pharmacology ; Aztreonam ; Aztreonam - pharmacology ; beta-Lactamase Inhibitors ; beta-Lactamase Inhibitors - pharmacology ; beta-Lactamases ; beta-Lactamases - drug effects ; Drug Combinations ; Drug Resistance, Multiple, Bacterial - drug effects ; Gram-Negative Bacterial Infections - drug therapy ; Gram-Negative Bacterial Infections - microbiology ; Humans ; Mechanisms of Resistance ; Microbial Sensitivity Tests ; Stenotrophomonas maltophilia ; Stenotrophomonas maltophilia - drug effects ; Stenotrophomonas maltophilia - isolation & purification</subject><ispartof>Antimicrobial agents and chemotherapy, 2017-10, Vol.61 (10)</ispartof><rights>Copyright © 2017 American Society for Microbiology.</rights><rights>Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-9b12b488142c620cfc590d9845616132d656d0eaf569eb57857be4bc8f710af53</citedby><cites>FETCH-LOGICAL-a418t-9b12b488142c620cfc590d9845616132d656d0eaf569eb57857be4bc8f710af53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610502/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610502/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28784669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mojica, Maria F</creatorcontrib><creatorcontrib>Papp-Wallace, Krisztina M</creatorcontrib><creatorcontrib>Taracila, Magdalena A</creatorcontrib><creatorcontrib>Barnes, Melissa D</creatorcontrib><creatorcontrib>Rutter, Joseph D</creatorcontrib><creatorcontrib>Jacobs, Michael R</creatorcontrib><creatorcontrib>LiPuma, John J</creatorcontrib><creatorcontrib>Walsh, Thomas J</creatorcontrib><creatorcontrib>Vila, Alejandro J</creatorcontrib><creatorcontrib>Bonomo, Robert A</creatorcontrib><title>Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for
is urgent. We demonstrate the
efficacy of aztreonam-avibactam (ATM-AVI) against
and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of
, addressing an unmet medical need.</description><subject>Anti-Bacterial Agents</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Azabicyclo Compounds</subject><subject>Azabicyclo Compounds - pharmacology</subject><subject>Aztreonam</subject><subject>Aztreonam - pharmacology</subject><subject>beta-Lactamase Inhibitors</subject><subject>beta-Lactamase Inhibitors - pharmacology</subject><subject>beta-Lactamases</subject><subject>beta-Lactamases - drug effects</subject><subject>Drug Combinations</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Gram-Negative Bacterial Infections - microbiology</subject><subject>Humans</subject><subject>Mechanisms of Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Stenotrophomonas maltophilia</subject><subject>Stenotrophomonas maltophilia - drug effects</subject><subject>Stenotrophomonas maltophilia - isolation & purification</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtrGzEUhUVJaVy3u6yDlgl0HEnWazaBwfQRCATidi00siZW0IwcSWNwf33U2DXJIitx7_10rnQOAGcYzTAm8qppFjOEhBAVFh_ABKNaVpzV_ARMEOK8ohLRU_A5pUdUalajT-CUSCEp5_UEPDRb12qTdQ_vbcoh2gTz2sLlmIzdZNc67_IOhg4uvBuc0R7epOB1LlxpLrMdQo5hsw59GHSCvfa5VOWWhjnA5m-Otgz6L-Bjp32yXw_nFPz58f334ld1e_fzZtHcVppimau6xaSlUmJKDCfIdKY8eFVLyjjmeE5WnPEVsrpjvLYtE5KJ1tLWyE5gVLrzKbje627GtrcrY4cctVeb6Hoddypop95OBrdWD2GrygLEECkCFweBGJ7GYonqXbHCez3YMCaFayLmiFFBC_ptj5oYUoq2O67BSP3LRpVs1Es2CouCX-5xnXqiHsMYh-LEe-z5628chf8HN38GfyeYwA</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Mojica, Maria F</creator><creator>Papp-Wallace, Krisztina M</creator><creator>Taracila, Magdalena A</creator><creator>Barnes, Melissa D</creator><creator>Rutter, Joseph D</creator><creator>Jacobs, Michael R</creator><creator>LiPuma, John J</creator><creator>Walsh, Thomas J</creator><creator>Vila, Alejandro J</creator><creator>Bonomo, Robert A</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam</title><author>Mojica, Maria F ; Papp-Wallace, Krisztina M ; Taracila, Magdalena A ; Barnes, Melissa D ; Rutter, Joseph D ; Jacobs, Michael R ; LiPuma, John J ; Walsh, Thomas J ; Vila, Alejandro J ; Bonomo, Robert A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-9b12b488142c620cfc590d9845616132d656d0eaf569eb57857be4bc8f710af53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anti-Bacterial Agents</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Azabicyclo Compounds</topic><topic>Azabicyclo Compounds - pharmacology</topic><topic>Aztreonam</topic><topic>Aztreonam - pharmacology</topic><topic>beta-Lactamase Inhibitors</topic><topic>beta-Lactamase Inhibitors - pharmacology</topic><topic>beta-Lactamases</topic><topic>beta-Lactamases - drug effects</topic><topic>Drug Combinations</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Gram-Negative Bacterial Infections - microbiology</topic><topic>Humans</topic><topic>Mechanisms of Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Stenotrophomonas maltophilia</topic><topic>Stenotrophomonas maltophilia - drug effects</topic><topic>Stenotrophomonas maltophilia - isolation & purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mojica, Maria F</creatorcontrib><creatorcontrib>Papp-Wallace, Krisztina M</creatorcontrib><creatorcontrib>Taracila, Magdalena A</creatorcontrib><creatorcontrib>Barnes, Melissa D</creatorcontrib><creatorcontrib>Rutter, Joseph D</creatorcontrib><creatorcontrib>Jacobs, Michael R</creatorcontrib><creatorcontrib>LiPuma, John J</creatorcontrib><creatorcontrib>Walsh, Thomas J</creatorcontrib><creatorcontrib>Vila, Alejandro J</creatorcontrib><creatorcontrib>Bonomo, Robert A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mojica, Maria F</au><au>Papp-Wallace, Krisztina M</au><au>Taracila, Magdalena A</au><au>Barnes, Melissa D</au><au>Rutter, Joseph D</au><au>Jacobs, Michael R</au><au>LiPuma, John J</au><au>Walsh, Thomas J</au><au>Vila, Alejandro J</au><au>Bonomo, Robert A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>61</volume><issue>10</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for
is urgent. We demonstrate the
efficacy of aztreonam-avibactam (ATM-AVI) against
and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of
, addressing an unmet medical need.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>28784669</pmid><doi>10.1128/AAC.00777-17</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2017-10, Vol.61 (10) |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5610502 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Anti-Bacterial Agents Anti-Bacterial Agents - pharmacology Azabicyclo Compounds Azabicyclo Compounds - pharmacology Aztreonam Aztreonam - pharmacology beta-Lactamase Inhibitors beta-Lactamase Inhibitors - pharmacology beta-Lactamases beta-Lactamases - drug effects Drug Combinations Drug Resistance, Multiple, Bacterial - drug effects Gram-Negative Bacterial Infections - drug therapy Gram-Negative Bacterial Infections - microbiology Humans Mechanisms of Resistance Microbial Sensitivity Tests Stenotrophomonas maltophilia Stenotrophomonas maltophilia - drug effects Stenotrophomonas maltophilia - isolation & purification |
| title | Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A58%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Avibactam%20Restores%20the%20Susceptibility%20of%20Clinical%20Isolates%20of%20Stenotrophomonas%20maltophilia%20to%20Aztreonam&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Mojica,%20Maria%20F&rft.date=2017-10-01&rft.volume=61&rft.issue=10&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.00777-17&rft_dat=%3Cproquest_pubme%3E1927305474%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1927305474&rft_id=info:pmid/28784669&rfr_iscdi=true |